WallStSmart

Abbott Laboratories (ABT)vsBrainsway Ltd (BWAY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 84779% more annual revenue ($44.33B vs $52.23M). ABT leads profitability with a 14.7% profit margin vs 14.6%. ABT trades at a lower P/E of 28.1x. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

BWAY

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 5.5Value: 3.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
BWAYSignificantly Overvalued (-178.3%)

Margin of Safety

-178.3%

Fair Value

$8.42

Current Price

$13.50

$5.08 premium

UndervaluedFair: $8.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

BWAY1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BWAY4 concerns · Avg: 2.8/10
EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

Market CapQuality
$536.38M3/10

Smaller company, higher risk/reward

P/E RatioValuation
75.9x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-2.02M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : BWAY

The primary concerns for BWAY are EPS Growth, Market Cap, P/E Ratio. A P/E of 75.9x leaves little room for execution misses.

Key Dynamics to Monitor

ABT profiles as a value stock while BWAY is a growth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.74 — expect wider price swings.

BWAY is growing revenue faster at 27.4% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Want to dig deeper into these stocks?